Assistant Professor, Department of Medicine (Nephrology)
The focuses of our scientific research have been development of chemical tools and potential pharmacological agents, application of those tools to characterize biological functions of specific genes and proteins, and evaluation of those agents as potential therapeutics targeting pathological conditions.
Previously we took an approach of high throughput screening and subsequent structure-relation studies of synthetic small molecules to develop inhibitors of specific genes using cell based assays. We have successfully developed potent inhibitors of prostaglandin transporter (PGT). Prostaglandins (PGs) are found in virtually all tissues and organs. They are autocrine and paracrine lipid mediators that act upon platelet, endothelium, uterine and mast cells, and diverse immune cells. The biological signals and physiological events they trigger range from pain and inflammation, to vasodilation and urinary sodium excretion, to cell growth and angiogenesis, and to thermogenesis and adipogenesis. PGT regulates the degradation and metabolism of PGs and thereby regulates PG signaling. We have demonstrated that PGT regulates angiogenesis in wound healing. Inhibition of PGT accelerates wound healing in diabetes. We are currently investigating the role of PGT in inflammation during wound healing. We will further elucidate the molecular mechanisms by which PGT modulates inflammation and angiogenesis in wound healing.
Recently we have started another major project, evaluation of natural compounds in modulation of metabolic syndromes including obesity and diabetes, and investigation of the molecular and cellular mechanisms by which those natural compounds improve those pathological conditions. We have identified magiferin that can protect against diet induced metabolic disorders. Our unbiased proteomics study revealed that mangiferin upregulates mitochondrial bioenergetics and downregualtes lipogenesis. Furthermore, we found that mangiferin is a novel activator of pyruvate dehydrogenase (PDH), which is the central gate-keeper of carbohydrate oxidative metabolism. We are currently investigating the molecular mechanisms of mangiferin modulation of mitochondrial bioengetics, lipogenesis and adipogenesis. We are also studying the pharmacokinetics and pharmacodynamics of mangifering, and developing mangiferin into a therapeutics for treatment of metabolic disorders.
Selected Recent Publications
More Information About Dr. Yuling Chi
Material in this section is provided by individual faculty members who are solely responsible for its accuracy and content.
Albert Einstein College of Medicine
Jack and Pearl Resnick Campus
1300 Morris Park Avenue
Ullmann Building, Room 615
Bronx, NY 10461